Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in TNBC Patients With Cardiac Risk
NCT06845319Phase 2Recruiting
- Sponsor
- Medical University of South Carolina
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Modality
- Immune Checkpoint Inhibitors, DNA Intercalators/Alkylators, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of carboplatin, paclitaxel, pembrolizumab in triple-negative breast cancer (TNBC), sponsored by Medical University of South Carolina. Started Oct 2025; status: recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06845319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06845319.